FDA did not place in the public docket trade secret and confidential commercial information, or information the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. An index listing these documents was created by the agency and is available to the public. However, unless the information in these documents was inextricably intertwined with the other information contained in the document, FDA redacted the trade secret, confidential commercial, or privacy information and placed the remainder of the document in the public docket.

In addition, FDA did not include in the public docket certain documents developed during the course of the agency's investigation of the tobacco industry because these documents could disclose the identity of sources that furnished information to the agency on a confidential basis. The agency's policy with respect to confidential sources in this investigation was discussed at the hearings before the House Subcommittee on Health and the Environment (see Regulation of Tobacco Products (Part 1) (March 25, 1994), pp. 35–37; Regulation of Tobacco Products (Part 3) (June 21, 1994), pp. 87–96).

In the agency's view, there can be no reasonable expectation of confidentiality for information submitted to a public docket in a rulemaking proceeding. Therefore, an agency is under no legal obligation to scrutinize documents submitted to a public docket to determine whether they may contain proprietary information. However, because it is aware of the sensitivity and importance of such information, FDA has long followed certain procedures to try to ensure that clearly proprietary information is not unwittingly made available to the public. FDA scans documents submitted to a docket for obvious trade secrets (e.g., formulas) or personal privacy information. In addition, any document marked confidential is referred to the appropriate Center Freedom of Information Act officer for a determination as to whether it would be exempt from public disclosure under Exemption 4 of the Freedom of Information Act (trade secrets and commercial or financial information obtained from a person and privileged or confidential). Before documents containing such information are placed on the record, the Center consults with the submitter to determine whether the submitter intended to make the document publicly available by placing it on the record. The agency is following these procedures in the tobacco proceeding.

Dated: December 21, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–31368 Filed 12–22–95; 11:18 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

FDA has established an Advisory Committee Information Hotline (the hotline) using a voice-mail telephone system. The hotline provides the public with access to the most current information on FDA advisory committee meetings. The advisory committee hotline, which will disseminate current information and information updates, can be accessed by dialing 1–800–741–8138 or 301–443–0572. Each advisory committee is assigned a 5-digit number. This 5-digit number will appear in each individual notice of meeting. The hotline will enable the public to obtain information about a particular advisory committee by using the committee's 5-digit number. Information in the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made.

MEETING: The following advisory committee meeting is announced:

Subcommittee Meeting of the National Mammography Quality Assurance Advisory Committee

Date, time, and place. January 10 and 11, 1996, 9 a.m., Hyatt Regency—Bethesda, Baccarat Suite, One Bethesda Metro Center, Bethesda, MD. A limited number of overnight accommodations have been reserved at the hotel. Attendees requiring overnight accommodations may contact the hotel at 301–657–1234, and reference the FDA Committee meeting block. Reservations will be confirmed at the group rate based on availability.

Type of meeting and contact person. Open public hearing, January 10, 1996, 9 a.m. to 10 a.m., unless public participation does not last that long; open subcommittee discussion, 10 a.m. to 5 p.m.; open subcommittee discussion, January 11, 1996, 9 a.m. to 1 p.m.; Charles K. Showalter, Center for Devices and Radiological Health (HFZ–240), Food and Drug Administration, 1350 Piccard Dr., Rockville, MD 20850, 301–594–3332, or FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572 in the Washington, DC area), National Mammography Quality Assurance Advisory Committee, code 12397.

General function of the committee. The committee advises on developing appropriate quality standards and regulations for the use of mammography facilities.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Those desiring to make formal presentations should notify the contact person before January 3, 1996, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Open subcommittee discussion. On January 10 and 11, 1996, the Access to Mammography Services subcommittee will meet. The subcommittee will discuss the ongoing work which is necessary to make the determinations and subsequently prepare the reports as mandated in the Mammography Quality Standards Act. Upon completion, the subcommittee report will be reviewed by the committee prior to submission to the Secretary and Congress.

FDA public advisory committee meetings may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. There are no closed portions for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public

administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: December 19, 1995.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 95–31369 Filed 12–22–95; 11:19 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[MT–070–95–1220–00]

Emergency Closure of Public Roads in Powell County, Montana

AGENCY: Bureau of Land Management, DOI.

ACTION: Notice of emergency closure of public access roads in Powell County, Montana.

SUMMARY: Notice is hereby given that certain public access roads in Powell County, Montana, are temporarily closed to all public use, including vehicle operation, winter recreational activities, and hiking and sightseeing from December 18, 1995, through March 15, 1996. The closure is made under the authority of 43 CFR 8364.1.

The public roads affected by this emergency closure are specifically identified as follows: BLM Road No. 2864 as it enters public lands and all spur roads accessed by this road.

The following persons, operating within the scope of their official duties, are exempt from the provisions of this closure order: BLM employees; local, state, and Federal law enforcement and fire protection personnel; the BLM timber purchaser, and its employees and subcontractors, within the area accessed by the closed road. Access by additional parties may be allowed, but must be approved in advance in writing by the Authorized Officer.

Any person who fails to comply with the provisions of this closure order may be subject to the penalties provided in 43 CFR 8360.0–7, which include a fine not to exceed $1,000 and/or imprisonment not to exceed 12 months.

The public roads temporarily closed to public use under this order will be posted with signs at points of public access.

The purpose of this emergency temporary closure is to protect persons from potential harm from logging operations, particularly the hazards associated with log hauling on winter roads.

DATES: This closure is effective from December 18, 1995, through March 15, 1996.

ADDRESSES: Copies of the closure order and maps showing the location of the closed roads are available from the Garnet Resource Area office, 3255 Fort Missoula Road, Missoula, Montana 59801.

FOR FURTHER INFORMATION CONTACT: Darrell Sall, Garnet Resource Area Manager, at (406) 329–3914.

Dated: December 15, 1995.

Darrell C. Sall,

Garnet Resource Area Manager.

[FR Doc. 95–31257 Filed 12–26–95; 8:45 am]

BILLING CODE 4310–DN–P

[OR–943–1430–01; GP6–0047]

Publication of List of Nationally Significant Lands To Be Retained and Confirmed to the United States Pursuant to the Act of July 2, 1993 and Final List of Base Land Parcels Relinquished to the United States Pursuant to the Act of June 4, 1897

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice.

SUMMARY: On July 2, 1993, Congress enacted Public Law 103–48 entitled ''An Act to Resolve the Status of Certain Lands Relinquished to the United States Under the Act of June 4, 1897 (30 Stat. 11, 36) and for Other Purposes.'' In compliance with the Act, notice is given of the following actions: (1) The list of Nationally Significant lands retained by the United States is incorporated in this notice as ''Table 1.'' By publication of this notice, all right, title, and interest in these lands is now vested and confirmed in the United States. (2) The Final List of base land parcels relinquished to the United States pursuant to the Act of June 4, 1897, is incorporated in this notice as ''Table 2.'' By publication of this notice, the United States quitclaims to the listed owners or entrymen or their successors all right, title, and interest of the United States in and to these parcels.

EFFECTIVE DATE: December 27, 1995.

ADDRESSES: Requests for additional information or other comments should be addressed to the Director (350), Bureau of Land Management, United States Department of the Interior, 1849 C Street NW., Washington, DC 20240.

FOR FURTHER INFORMATION CONTACT: Jeff Holdren in the Bureau of Land Management (BLM) Washington Office (202) 452–7779, Bill Bliesner in the BLM Oregon/Washington State Office (503) 952–6157, or John Beck in the BLM California State Office (916) 979–2858.

SUPPLEMENTARY INFORMATION:

Background

In compliance with the Act of July 2, 1993, Public Law 103–48, (hereafter referred to as the Act) the Bureau of Land Management (BLM) published in the December 30, 1993 issue of the Federal Register (58 FR 69402), the Initial List of base land parcels that were